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Editorial on the Research Topic
Advances in Cancer Stem Cell Biology
The World Health Organization (WHO) reports that an estimated 9.6 million people died from
cancer in 2018 (Bray et al., 2018). This estimate includes patients who had a diverse range of
different types of cancers, including those arising in the lung, large intestine, stomach, liver, and
breast cancer. For all of these tumors, the standard treatment options are surgery, radiotherapy,
and chemotherapy. Several factors may influence the prognosis of a cancer patient. One particular
factor that correlates with patients’ survival is related to the biology of the tumor mass, i.e.,
whether the tumor grows slowly, fast, or has the capacity to relocate (Zhang et al., 2020; Thurmaier
et al., 2021). The biologies of the different types of cancers are at the core connected through the
abnormalities of 10 cellular pathways known as the hallmarks of cancer (Hanahan and Weinberg,
2011). Deregulation in these pathways is correlated with chemo and radio resistance (Buckley et al.,
2020). A particular pathway that involves sustaining proliferative signaling and enabling cancer
cells to behave similarly to embryonic stem cells has been of great interest in the area of translation
oncology. Single-cell analysis of different cancers has shown clearly the existence and the diversity
of a stem cell program in many tumor cells (Patel et al., 2014; Filbin et al., 2018). Targeting the
diverse types of Cancer Stem Cells (CSCs) in IDH-wildtype GlioblastomaMultiforme (GBM) using
combination therapy has been shown to be synergistic (Wang et al., 2019). Thus, characterizing the
properties of CSCs is critical to improving future CSCs-targeting therapies. However, whether the
activation of a deregulated stem cell program in CSCs is transient or stable remains to be addressed
(Neftel et al., 2019).
The Advances in Cancer Stem Cell Biology topic aimed to provide a recent overview on the
molecular biology of CSCs. Different approaches were used in published manuscripts from theory
to bioinformatics and to experiments.
Using bioinformatics tools, Sang et al. aimed at identifying markers for CSCs that
correlate with immune infiltrates in hepatocellular carcinoma (HCC) and poor patient
survival. They utilized the Oncomine database, Gene Expression Profiling Interactive Analysis
(GEPIA), and Integrative Molecular Database of Hepatocellular Carcinoma (HCCDB) to
analyze the expression of hepatocellular CSC (HCSC) markers in 364 liver cancer samples.
The correlation of HCSC markers to tumor-infiltrating immune cells was tested by Tumor
Immune Estimation Resource (TIMER). Out of 10 differentially deregulated HCSC markers,
3 (CD24, SOX9, and SOX12) were highly expressed and had a positive correlation
with poor prognosis. In contrast, the expression of CD13, CD34, and ALDH1A1 was
associated with prolonged overall survival. The authors noted that SOX12 in particular
might constitute a therapeutic target for hepatocellular carcinoma. Complementary to
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that work is the Li and Zhu manuscript, which reviewed recent
advances in experimental studies on liver CSCs. They showed an
update on the latest advances in experimental studies on non-
coding RNAs (ncRNAs), oncogenes, and oncoproteins, with a
particular focus on three pathways: the Wnt/β-catenin signaling
pathway, phosphatidylinositol 3-kinase (PI3K)/protein kinase B
(Akt) signaling pathway, and interleukin 6/Janus kinase 2/signal
transducer and activator of transcription 3 (IL6/JAK2/STAT3)
signaling pathway. Known associated roles for more than 30
CSC-related genes were discussed in detail. In particular, they
conclude that octamer 4 (OCT4) and NANOG are important
functional genes that play a pivotal role in liver CSC regulation
and HCC prognosis.
Another bioinformatics-based paper, published by Tian et al.,
applied a weighted gene co-expression network analysis on
gene expression data sets from head and neck squamous cell
carcinomas (HNSCC) to define an mRNA expression-based
stemness index consisting of genes that served as prognostic
markers. Raw data for 643 samples were downloaded from
the Cancer Genome Atlas (TCGA) database and the Gene
Expression Omnibus (GEO) website. The study showed that
the combined deregulated expression of eight stem-cell-related
markers (RGS16, LYVE1, hnRNPC, ANP32A, A1MP1, ZNF66,
PIK3R3, and MAP2K7) has a powerful capacity for overall
survival prediction. They support their bioinformatics data by
detecting the level of expression in HNSCC cell lines. The authors
concluded that their proposed model could contribute to a better
understanding of the role of HNSCC stem cells in developing
targeted therapy.
An experimentally based approach was presented in the
manuscript authored by Li et al. This work investigated
the association of SET Domain Containing 2 (SETD2) gene
mutations/variants with clinical features and prognosis in
patients with Myelodysplastic syndrome (MDS). SETD2 is a
transcriptional regulator and has been previously shown to
be required for the self-renewal of hematopoietic stem cells
(HSCs), and SETD2-deficient HSCs were shown to contribute
to the development of MDS. Using targeted next-generation
sequencing, the results indicated that out of 203 patients with
MDS, 37 patients had SETD2 gene mutations/variants, and
these patients exhibited a significantly increased frequency of
TP53 mutations. Low expression of SETD2 in patient tumor
cells was identified as a risk factor for progression-free survival
(PFS). The study concluded that SETD2 deficiency contributes to
genomic instability and is associated with unfavorable prognosis
in patients with myelodysplastic syndrome.
Three more review articles were published in this collection.
The first was a mini review by Azzarelli, which discussed the
emerging 3D models of glioblastoma that overcome certain
limitations of monolayer cultures. The author concluded that
glioblastoma brain organoids provide the opportunity to study
CSC lineages and serve as tools to predict tumor progression and
treatment response. In a second review, Xu et al. discussed the
role of N6-methyladenosine (m6A) in the differentiation of CSCs.
The authors highlighted that targetingm6Amodification of CSCs
constitutes a yet not fully explored option for drug treatment
of cancer. The third review was presented by Alhabbab, and it
described how CSCs employ various mechanisms to modulate
the immune system response. The review outlined the recent
knowledge for the interactions between CSCs’ common markers,
including CD133, CD90, EpCAM, CD44, ALDH, and EGFRVIII,
and the immune system. Current information on CAR T cell
genetic engineering and signaling, CAR T cells, and the barriers
in using CAR T cells as immunotherapy to treat solid cancers in
the context of targeting CSCs were detailed.
Finally, in a theory-based article, Manzo investigated the
nature of tumor growth within a mathematical model, which
assumes tumors encompass CSCs that behave similarly to
para-embryonic stem cells and divide into a hierarchic
sequence of CSCs and non-CSCs. Tabulating theoretical data
using this model, the author identified defined mathematical
relationships between CSCs and non-CSCs that were similar to
experimental data. The model explains tumor progression in
a modular way that recalls the propagation of tumor spheres
in vitro. Furthermore, the author discussed similar features,
including nature form, dimension, cell distribution, and layer
compartmentation for avascular tumors, tumor spheres, and
preimplantation blastocysts. The author concluded that the
presented mathematical model provides further support for the
para-embryonic nature of the cancer process.
The research on CSCs is ongoing, and several concepts
still remain to be addressed or fully explained. For example,
what combinations of markers define different types of CSCs,
and how does the “combined markers identity tag” correlate
with therapeutic prognosis? Perhaps next-generation single-
cell sequencing in combination with multiplex protein array
technology could shed more light on the characteristics of CSCs
and CSC markers. A unified CSC-specific interactive database
for the mutational signatures and genomic instability of CSCs is
likely to improve cancer research. Some questions remain: How
do CSCs contribute to metastasis, and what are the therapeutics
that can be given to combat CSCs movement and colonization?
How can the gene expression profile of CSCs be stabilized and
prevented from shifting in response to the microenvironment?
What are the clinically relevant CSCs models that provide
highly efficient translational protocols that can be utilized in a
clinical setting?
Taken together, the variety of the authors’ topic contributions,
either by focused reviews, theoretical considerations, or research
articles, has shed light on current advances in CSC biology and
support further approaches for integrative CSC research.
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